PathAI Announces Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON–(BUSINESS WIRE)–PathAI, a global leader in artificial intelligence (AI)-based technology for pathology, today announced that its recent research will be presented at the 2022 AACR Annual Meeting, being held at New Orleans from April 8-13, 2022. PathAI will share a total of six posters, three of which were developed in collaboration with pharmaceutical partners. These new findings have promising implications for improving the diagnosis and treatment of multiple cancer subtypes through the use of AI-powered digital pathology.

“Our research demonstrates how PathAI algorithms can discover new information or generate important molecular inferences from standard pathology samples that could not be identified using traditional pathology interpreted manually or with approaches more expensive and less accessible molecules,” said Mike Montalto, Chief Scientific Officer of PathAI. “This translational information is critically important to accelerating drug development and getting lifesaving drugs to patients faster.”

A key example of this ability is highlighted in the poster, “AI-powered nuclear morphology segmentation and analysis predict genomic and clinical markers in multiple cancer types”, who describes PathAI’s machine learning-based nuclear segmentation model that links features of nuclear morphology with clinically relevant molecular and genomic markers in multiple tumor types.

The model was trained using more than 29,000 annotations across multiple cancer types as well as five non-cancerous tissues, to identify nuclei in any tissue type. Features related to nuclear shape, texture and color were automatically extracted from the model and assessed for their ability to predict genomic and molecular markers important for treatment selection and disease prognosis. Applied to breast, lung, and prostate tumor tissue, these models have identified key combinations of predictive nuclear features of biomarkers, including whole genome doubling, homologous recombination deficiency, HER2 positivity, or elevated Gleason grade. . These models could provide a way to quickly genotype patients to select the most appropriate treatments without the need for additional tissue samples or sequencing protocols.

The full list of PathAI poster presentations is highlighted below. More information on each abstract can be found here.

Title: Quantification of TGFβ Protein Levels and Digital Pathology-Based Immune Phenotyping Reveal Biomarkers for Patient Selection on TGF-β Blockade Therapy in NSCLC

  • Session date and time: Online only. E-poster available April 8, 2022, 12:00 p.m. CT.
  • Abstract: 5099

Developed in partnership with Sanofi

Title: Machine Learning Models Identify Histological Features That May Predict KEAP1 Mutations in Lung Adenocarcinoma

  • Session date and time: April 10, 2022, 1:30 p.m. – 5:00 p.m. CST
  • Summary: 449

Title: AI-powered nuclear morphology and segmentation predict genomic and clinical markers in multiple cancer types

  • Session date and time: April 10, 2022, 1:30 p.m. – 5:00 p.m. CST
  • Summary: 464

Title: AIM PD-L1-NSCLC: Artificial Intelligence-Based PD-L1 Quantification for Accurate Prediction of Tumor Proportion Score in Various Multi-Stain Clinical Tissue Samples

  • Session date and time: April 10, 2022, 1:30 p.m. – 5:00 p.m. CST
  • Summary: 471

Title: AI-assisted assessment and manual PD-L1 assessment are comparable in predicting response to neoadjuvant atezolizumab in patients (pts) with non-squamous non-small cell lung cancer (NSCLC ) resectable

  • Date and time: April 11, 2022, 9:00 a.m. to 12:30 p.m. CST
  • Summary: CT112

Developed in partnership with Genentechmember of the Roche group

Title: Application of an interpretable neural graph network to predict gene expression signatures associated with tertiary lymphoid structures in histological images

  • Session date and time: April 11, 2022, 1:30 p.m. – 5:00 p.m. CST
  • Summary: 1922

Posters will be available to registered attendees for on-demand viewing on the AACR website on April 8, 2022 at 1:00 p.m. ET.

About PathAI

PathAI is a leading provider of AI-based research tools and services for pathology. PathAI’s platform promises substantial improvements in diagnostic accuracy and treatment efficiency for diseases like cancer, by leveraging modern machine and deep learning approaches. Based in Boston, PathAI works with leading life science companies and researchers to advance precision medicine. To learn more, visit

Previous Avian flu: another farm in the London area affected by an epidemic
Next Tuesday music events, more planned in April in the Van Aken district: Press Run